Related Experiment Videos
Vancomycin toxicity: a prospective study
Abstract:
A prospective study of 34 patients treated with 39 courses of intravenous vancomycin, was undertaken in order to assess toxicity. Six patients received vancomycin alone and 27 courses were associated with aminoglycoside administration either concurrently or within two weeks of the first dose of vancomycin. Hearing loss was slight and uncommon; patients were unaware of its occurrence. Tinnitus and dizziness was noted by two patients and resolved on withdrawal of vancomycin. Diminution of renal function was seen both during (7%) and after (9%) vancomycin therapy. A striking feature of these patients with renal deterioration was the severity of their underlying disease. No evidence of synergistic toxicity between vancomycin and aminoglycosides was seen.
Insights
This study assessed vancomycin toxicity in 34 patients. Vancomycin showed minimal hearing loss and rare renal function decline, with no synergistic toxicity observed with aminoglycosides.
Area of Science:
- Pharmacology
- Nephrology
- Ototoxicology
Background:
- Intravenous vancomycin is a critical antibiotic for serious Gram-positive infections.
- Assessing vancomycin's toxicity profile, especially in combination with other nephrotoxic agents like aminoglycosides, is crucial for patient safety.
Purpose of the Study:
- To evaluate the toxicity of intravenous vancomycin in a prospective patient cohort.
- To specifically assess ototoxicity (hearing loss, tinnitus, dizziness) and nephrotoxicity (renal function decline).
- To investigate potential synergistic toxicity between vancomycin and concurrent or sequential aminoglycoside administration.
Main Methods:
- Prospective study design involving 34 patients receiving 39 courses of intravenous vancomycin.
- Categorization of vancomycin administration: alone or in combination with aminoglycosides.
- Monitoring for adverse events including hearing impairment and changes in renal function.
Main Results:
- Hearing loss was infrequent and mild, with patients often unaware.
- Two patients experienced transient tinnitus and dizziness, resolving upon vancomycin withdrawal.
- Renal function deterioration occurred in 7% during and 9% after vancomycin therapy, often associated with severe underlying conditions.
- No evidence of increased toxicity when vancomycin was combined with aminoglycosides.
Conclusions:
- Intravenous vancomycin exhibits a generally favorable toxicity profile regarding ototoxicity and nephrotoxicity in this cohort.
- The severity of underlying illness appears to be a significant factor in vancomycin-associated renal function decline.
- Vancomycin can be safely administered with aminoglycosides without apparent synergistic toxicity.